Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-02

Clinical Trial Update: A Study of Lasmiditan (LY573144) Over Four Migraine Attacks [Phase 3]

View source ↗

Summary

Phase 3 trial update on lasmiditan (LY573144) across four migraine attacks with completed results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lasmiditan (Lasmiditan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2021-07-02